NASDAQ:ATHE Alterity Therapeutics (ATHE) Stock Price, News & Analysis → The Key to this $10 Trillion Tech Boom (From Porter & Company) (Ad) Free ATHE Stock Alerts $1.89 -0.05 (-2.58%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$1.82▼$1.9250-Day Range$1.85▼$2.9452-Week Range$1.55▼$5.41Volume13,646 shsAverage Volume12,919 shsMarket Capitalization$8.83 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Alterity Therapeutics alerts: Email Address Alterity Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside111.6% Upside$4.00 Price TargetShort InterestHealthy0.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.25) to ($0.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.02 out of 5 stars 3.5 Analyst's Opinion Consensus RatingAlterity Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAlterity Therapeutics has received no research coverage in the past 90 days.Read more about Alterity Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.25% of the float of Alterity Therapeutics has been sold short.Short Interest Ratio / Days to CoverAlterity Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alterity Therapeutics has recently decreased by 40.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlterity Therapeutics does not currently pay a dividend.Dividend GrowthAlterity Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATHE. Previous Next 2.2 News and Social Media Coverage News SentimentAlterity Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Alterity Therapeutics this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alterity Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders38.80% of the stock of Alterity Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.14% of the stock of Alterity Therapeutics is held by institutions.Read more about Alterity Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Alterity Therapeutics are expected to grow in the coming year, from ($0.25) to ($0.13) per share.Price to Book Value per Share RatioAlterity Therapeutics has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyThe last Republican president?History shows Donald Trump is poised to go down as the last Republican President for a generation or more. How is this possible, with Biden so unpopular, and Trump running at least neck-in-neck with him in polls?This presentation explains exactly why. About Alterity Therapeutics Stock (NASDAQ:ATHE)Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.Read More ATHE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATHE Stock News HeadlinesJune 14 at 6:40 AM | americanbankingnews.comAlterity Therapeutics Limited (NASDAQ:ATHE) Sees Significant Decline in Short InterestJune 12 at 7:22 PM | globenewswire.comAlterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' WebinarMay 29, 2024 | globenewswire.comAlterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History StudyMay 8, 2024 | globenewswire.comAlterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third ReviewApril 30, 2024 | globenewswire.comAppendix 4C – Q3 FY24 Quarterly Cash Flow ReportApril 29, 2024 | finance.yahoo.comAlterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s AtaxiaApril 29, 2024 | globenewswire.comAlterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich's AtaxiaApril 17, 2024 | finance.yahoo.comAlterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual MeetingApril 10, 2024 | globenewswire.comAlterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024April 5, 2024 | finance.yahoo.comAlterity Therapeutics Limited (ATHE)March 26, 2024 | globenewswire.comAlterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive RefundMarch 24, 2024 | morningstar.comAlterity Therapeutics Ltd ADR ATHEMarch 22, 2024 | seekingalpha.comATHE Alterity Therapeutics LimitedMarch 22, 2024 | wsj.comAlterity Therapeutics Ltd. ADRFebruary 23, 2024 | msn.comAlterity Therapeutics drops on capital raiseFebruary 22, 2024 | benzinga.comAlterity Therapeutics Stock (NASDAQ:ATHE), Short Interest ReportFebruary 20, 2024 | finance.yahoo.comAlterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingFebruary 20, 2024 | globenewswire.comAlterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingJanuary 29, 2024 | finance.yahoo.comAlterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This WeekJanuary 22, 2024 | finance.yahoo.comAlterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesDecember 21, 2023 | finanznachrichten.deALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Appoints Phillip Hains as Chief Financial OfficerDecember 4, 2023 | finance.yahoo.comAlterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical ProgressDecember 4, 2023 | marketwatch.comAlterity Therapeutics Shares Up Fivefold on New Parkinson's Drug DataDecember 4, 2023 | msn.comWhy Is Neurodegenerative Disease-Focused Alterity Therapeutics Stock Trading Over 200% Higher Today?December 4, 2023 | finance.yahoo.comBiotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial DataSee More Headlines Receive ATHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alterity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/14/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATHE CUSIPN/A CIK1131343 Webwww.alteritytherapeutics.com Phone(139) 349-4906Fax61-3-9348-0377Employees11Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+111.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.89 Quick RatioN/A Sales & Book Value Annual Sales$3.37 million Price / Sales2.62 Cash FlowN/A Price / Cash FlowN/A Book Value$3.78 per share Price / Book0.50Miscellaneous Outstanding Shares4,670,000Free Float2,859,000Market Cap$8.83 million OptionableNot Optionable Beta0.83 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Geoffrey Paul Kempler B.Sc. (Age 69)Co-Founder & Non-Executive Chairman Comp: $204.63kDr. David A. Stamler M.D. (Age 63)Chief Executive Officer Comp: $604.79kMr. Phillip Allen Hains BBus(Acc) (Age 65)C.A., M.B.A., CFO & Company Secretary Dr. Rudolph Emile Tanzi Ph.D. (Age 65)Chief Scientific Advisor and Member of Research & Development Advisory Board Dr. Steven D. TargumChief Medical AdvisorDr. Robert ChernyHead of ResearchMore ExecutivesKey CompetitorsNRx PharmaceuticalsNASDAQ:NRXPMarker TherapeuticsNASDAQ:MRKRVYNE TherapeuticsNASDAQ:VYNENeoleukin TherapeuticsNASDAQ:NLTXProMIS NeurosciencesNASDAQ:PMNView All Competitors ATHE Stock Analysis - Frequently Asked Questions Should I buy or sell Alterity Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alterity Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATHE shares. View ATHE analyst ratings or view top-rated stocks. What is Alterity Therapeutics' stock price target for 2024? 1 analysts have issued 1 year target prices for Alterity Therapeutics' stock. Their ATHE share price targets range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 111.6% from the stock's current price. View analysts price targets for ATHE or view top-rated stocks among Wall Street analysts. How have ATHE shares performed in 2024? Alterity Therapeutics' stock was trading at $2.49 on January 1st, 2024. Since then, ATHE stock has decreased by 24.1% and is now trading at $1.89. View the best growth stocks for 2024 here. Are investors shorting Alterity Therapeutics? Alterity Therapeutics saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 20,800 shares, a decrease of 40.6% from the May 15th total of 35,000 shares. Based on an average daily trading volume, of 76,100 shares, the short-interest ratio is presently 0.3 days. Approximately 0.3% of the shares of the stock are short sold. View Alterity Therapeutics' Short Interest. When did Alterity Therapeutics' stock split? Alterity Therapeutics's stock reverse split before market open on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Alterity Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alterity Therapeutics investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY). How do I buy shares of Alterity Therapeutics? Shares of ATHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATHE) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.